Costs of congenital rubella syndrome (CRS) in Oman: Evidence based on long-term follow-up of 43 children
Costs of congenital rubella syndrome (CRS) in Oman: Evidence based on long-term follow-up of 43 children
复制标题
DOI：
10.1016/j.vaccine.2006.05.089
复制
发表时间：
2006-09-29
期刊：
影响因子：
5.5
通讯作者：
Robertson, Susan E.
中科院分区：
文献类型：
--
作者：
Al-Awaidy, Salah;Griffiths, Ulla K.;Robertson, Susan E.
作为消除风疹和先天性风疹综合征国家计划的一部分，阿曼建立了全国风疹和先天性风疹综合征病例登记册。截至2005年5月，该登记处包括43例幸存的CRS病例，平均年龄为11.9岁。临床检查发现，84%有眼部缺陷，84%有听觉/语言缺陷，70%有神经系统表现，42%有心脏缺陷。终身医疗，特殊教育和康复费用进行了评估。使用3%的贴现率，每个存活的CRS患者的平均直接终身成本估计为18，644美元。如果将预计因CRS而损失的生产力包括在内，则每个CRS幸存患者的平均贴现直接和间接终身成本为98 734美元。(c)2006爱思唯尔有限公司保留所有权利。
As part of the national plan for elimination of rubella and congenital rubella syndrome (CRS), Oman established a national registry of CRS cases. As of May 2005, the registry included 43 surviving CRS cases, with a mean age of 11.9 years. Clinical examinations found that 84% had ocular defects, 84% had auditory/speech defects, 70% had neurological manifestations, and 42% had cardiac defects. Lifetime medical, special education, and rehabilitation costs were assessed. Using a discount rate of 3%, the average direct lifetime cost per surviving CRS patient was estimated at US$18,644. When including predicted lost productivity due to CRS, the average discounted direct and indirect lifetime costs per surviving CRS patient amounted to US$ 98,734. (c) 2006 Elsevier Ltd. All rights reserved.